Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.
While researchers and drug developers are identifying molecular targets in a specific cancer subtype to improve outcomes, they have also been innovating on the clinical trial design front. At a late session during the 58th American Society of Hematology Annual Meeting & Exposition, being held December 3-6, in San Diego, California, representatives from 2 national clinical trials, Beat Acute Myeloid Leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided insight on trial design and progress reports.
Providing an update on the Beat AML trial was Brian Druker, MD, director of the Knight Cancer Institute at Oregon Health & Science University, which is collaborating with the Leukemia and Lymphoma Society on the trial.
Providing background on the disease, Druker said that AML is the most common leukemia in adults, with the median age at diagnosis of 67 years. However, despite all the progress with characterizing the molecular abnormalities associated with the disease, progress on the treatment front has been dismal.
“Treatment evolution for AML has lacked significantly,” Druker said, adding that disease outcomes have remained poor over the past decade and there have been very few approvals. “The fact that AML is a very heterogeneous disease could also have a role to play,” Druker added.
While the dozens of different molecular subtypes make it a very complicated disease to treat, Druker listed a few targeted agents that have seen some progress in treating AML, including syk inhibitors, IDH1/2 agents, kinases (FLT3, KIT), and the more recent immune checkpoint inhibitors.
Additional, conducting a clinical trial for AML remains a hurdle, Druker noted: “Challenges include the fact that the standard of care remains beneficial, single agent treatment will not be beneficial, genomic assays take long to deliver and trials are hard to recruit for.”
With all these challenges, the Beat AML trial has been designed with the following objectives:
The trial has a multi-arm protocol, with:
Trial eligibility criteria are straightforward: patients 60 years and older who have previously untreated AML can participate. Following genomic analysis of their tissue, patients will be assigned to independent treatment arms in the protocol.
“The primary objective of the Beat AML trial is to assess feasibility of trial design,” Druker said. “Secondary objectives are to determine how many patients can be successfully enrolled, determine if patients can reach allogenic stem cell transplant, and assess impact on outcomes.”
He listed the following treatment substudies and their start date:
CD33 (BI 836858) + Aza
CD200 (Samalizumab) + induction
CD33 (BI 836858) + Aza
Syk inhibitor (Entosplentinib)
IDH 2 inhibitor (AG221) +/- Aza
FLT3 inhibitor + decitabine
IDH 1 mutation
IDH 1 inhibitor
For biomarker assessment, Druker said that cytogenetics assays will be local. Meanwhile, biopsy samples will be sent to Foundation Medicine to conduct a more long-term 300-gene panel assay. “However, critical genes will be assayed by the company in 7 days, including NPM1, IDH1/2, and FLT3.”
Order of patient assignment to a treatment arm will be based on:
Trial endpoints are standard, Druker told the audience, and include primary endpoints of complete response and response duration. Secondary endpoints include event-free survival, progression-free survival (PFS), overall survival, and minimal residual disease.
Still in its early stages of conception, Beat AML has “enrolled 4 patients till date,” Druker said. “The goal is to allow patients to be enrolled in active treatment arms and the master protocol allows switching between the arms.” He added that in the future, the trial would like to include additional arms on the protocol and also test novel combinations.
The second presentation of the session, by Keith Flaherty, MD, provided an update on the NCI-MATCH trial. Flaherty, director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital and associate professor of Medicine at the Harvard Medical Center, also chairs ECOG-ACRIN, which is collaborating with NCI on this trial.
Flaherty was very excited to share with the audience that the trial was expected to hit it’s 6000 patient enrollment target in the next 6 months. “We are currently enrolling 120-150 patients being each week,” he said.
“The objective of this phase 2 precision-med trial is to match genetic abnormalities of tumors with a suitable targeted drug, regardless of cancer type,” Flaherty explained. “It’s a signal-finding trial, meaning promising treatments can be expanded to a more definitive trial in the future.”
Eligibility criteria for enrollment in NCI-MATCH include adults over 18 years, those who lack or have exhausted standard treatment, patients who have developed either solid or liquid tumors, patients with a good ECOG performance status and adequate organ function, and patients who can tolerate being off treatment for 6 weeks.
Flaherty listed the following criteria for source material for genetic and immunohistochemistry analysis:
Level 1: gene variant credentialed for selection of an approved drug
Level 2a: variant eligible for an ongoing clinical trial
Level 2b: variant identified in an N of one response
Level 3: preclinical inferential data
The following Levels of Evidence strategy is being implemented by NCI-MATCH:Â
Level 1: FDA-approved for any indication for that target
Level 2: agent met a clinical endpoint with evidence of target inhibition
Level 3: agent demonstrated evidence of clinical activity with evidence of target inhibition at some level
Levels of Evidence for drugs in NCI-MATCH include:
Among the 6000 patients that will be the final enrollment, there are 929 treatment enrollments anticipated across 24 gene abnormalities that are currently being evaluated as part of this trial. Primary trial endpoint is overall response rate, with secondary endpoints of PFS, time to progression, toxicity, and biomarker expression.
Flaherty explained that the trial demands 4 core biopsies at initial entry, which are shipped to the central lab at MD Anderson. H&E sections are assayed by a pathologist for tumor type, content, percent necrosis, and inflammation and scanned into a high-resolution image database. RNA and DNA are then extracted and then distributed to a network of laboratories.
Currently, immunohistochemistry analysis is being conducted for PTEN, MLH1, MSH2, and Rb. “We have also added mismatch repair genes and are evaluating PD-1 expression,” he added. The trial has incorporated a customized Oncomine assay, which has been developed by Thermo Fischer. The panel includes 143 genes, 2530 amplicons in the DNA panel, and 207 amplicons in the RNA panel.
Flaherty provided a very uplifting picture on patient wait times:
“As of November 27, we have 3149 patients with tumor samples, of whom 2589 have received their test results; 468 had a genetic abnormality matching an available treatment,” Flaherty told the audience. “Twenty-two percent of currently enrolled patients have a gene abnormality that matches one being studied in the trial,” he added.
Although the trial currently has 24 arms, this number is expected to increase.